EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokoll

Combination Therapy of Resilience Intervention with Biologics in Crohn's Disease (CATHARSIS): Study protocol for a randomized controlled trial

Laurie Keefer, Ryan Ungaro, Ayanna Lewis, Josie Lee, Candela de Amorrortu, Taryn Lores, Tina Siganporia, Saurabh Mehandru, Francesca Petralia, Jean-Frederic Colombel

Contemporary Clinical Trials · 2026

DOI: 10.1016/j.cct.2025.108151 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2026. Verfasst von Laurie Keefer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, Inflammatory Bowel Disease Center, 17 E. 102nd Street, New York, NY, United St…. Hauptthemen laut MEDLINE: Crohn Disease, Resilience, Psychological, Biological Products, Behavior Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Leona M and Harry B Helmsley Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Remission rates in Crohn's disease (CD) with standard therapies have plateaued in recent decades. There is a need to investigate more innovative strategies to raise the "therapeutic ceiling". Combining orthogonal treatments that target differing pathways of disease pathogenesis may maximize synergistic therapeutic efficacy. In particular, the addition of interventions that target the gut-brain axis warrant investigation. Our overarching goal is to demonstrate the value of a new "combination therapy" that addresses psychological and physical health simultaneously, targeting the gut-brain axis, to improve CD outcomes. We will test the efficacy of combining brain-gut behavior therapy with biologic treatment in a randomized, controlled clinical trial, following behavioral clinical trial guidelines for gastroenterology. METHODS: We will recruit 170 adults with CD aged between 18 and 80 years starting an anti-tumor necrosis factor or anti-interleukin-23 medication. Participants will be randomized in a 1:1 ratio to receive a program of either brain-gut behavioral therapy (intervention group) or emotional support (time and attention control group). Both programs consist of seven sessions within a 12-week period. Patient-reported outcomes including well-being and disease activity will be measured at weeks 0, 12, 24, 36, and 52, with the primary outcomes reflected at week 24. Outcomes will be evaluated for group X time interactions. CONCLUSIONS: This trial will be the first of its kind to rigorously evaluate the efficacy of a treatment approach that combines brain-gut behavioral therapy and biologics for people with CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseResilience, PsychologicalBiological ProductsBehavior TherapyHumansAdultMiddle AgedYoung AdultRandomized Controlled Trials as TopicCombined Modality TherapyFemaleMaleAdolescentAgedPatient Reported Outcome MeasuresQuality of LifeAged, 80 and overTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

Brain-gut behavior therapyEmotional well-beingInflammatory bowel diseaseMind-body interventionSelf-management skills

Substanzen

Biological ProductsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, Inflammatory Bowel Disease Center, 17 E. 102nd Street, New York, NY, United States of America. Electronic address: laurie.keefer@mssm.edu.
  • Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, Inflammatory Bowel Disease Center, 17 E. 102nd Street, New York, NY, United States of America.
  • Department of Genetic and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.

Förderung

  • Leona M and Harry B Helmsley Charitable Trust

Zitieren

APA

Keefer, L., Ungaro, R., Lewis, A., Lee, J., de Amorrortu, C., Lores, T., Siganporia, T., Mehandru, S., Petralia, F., & Colombel, J. F. (2026). Combination Therapy of Resilience Intervention with Biologics in Crohn's Disease (CATHARSIS): Study protocol for a randomized controlled trial. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2025.108151

Vancouver

Keefer L, Ungaro R, Lewis A, Lee J, de Amorrortu C, Lores T, et al. Combination Therapy of Resilience Intervention with Biologics in Crohn's Disease (CATHARSIS): Study protocol for a randomized controlled trial. Contemporary Clinical Trials. 2026. doi:10.1016/j.cct.2025.108151

BibTeX
@article{Keefer2026,
  author = {Keefer, Laurie and Ungaro, Ryan and Lewis, Ayanna and Lee, Josie and de Amorrortu, Candela and Lores, Taryn and Siganporia, Tina and Mehandru, Saurabh and Petralia, Francesca and Colombel, Jean-Frederic},
  title = {Combination Therapy of Resilience Intervention with Biologics in Crohn's Disease (CATHARSIS): Study protocol for a randomized controlled trial},
  journal = {Contemporary Clinical Trials},
  year = {2026},
  doi = {10.1016/j.cct.2025.108151}
}
Kostenlos starten →